CN107530368A - 抗癌组合物及其用途 - Google Patents

抗癌组合物及其用途 Download PDF

Info

Publication number
CN107530368A
CN107530368A CN201680021393.1A CN201680021393A CN107530368A CN 107530368 A CN107530368 A CN 107530368A CN 201680021393 A CN201680021393 A CN 201680021393A CN 107530368 A CN107530368 A CN 107530368A
Authority
CN
China
Prior art keywords
pgg
methanol
compound
cell
gnmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680021393.1A
Other languages
English (en)
Inventor
陈宜民
颜嘉宏
卢重光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaohsiung Medical University
Original Assignee
Kaohsiung Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaohsiung Medical University filed Critical Kaohsiung Medical University
Publication of CN107530368A publication Critical patent/CN107530368A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明揭示一种抗癌组合物及其用途，该组合物具有抑制致癌物的作用。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201680021393.1A 2015-04-16 2016-04-14 抗癌组合物及其用途 Pending CN107530368A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148238P 2015-04-16 2015-04-16
US62/148,238 2015-04-16
PCT/CN2016/079289 WO2016165630A1 (zh) 2015-04-16 2016-04-14 抗癌组合物及其用途

Publications (1)

Publication Number Publication Date
CN107530368A true CN107530368A (zh) 2018-01-02

Family

ID=57125647

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680021393.1A Pending CN107530368A (zh) 2015-04-16 2016-04-14 抗癌组合物及其用途

Country Status (5)

Country Link
US (1) US11000535B2 (zh)
JP (1) JP6692830B2 (zh)
CN (1) CN107530368A (zh)
TW (1) TWI626051B (zh)
WO (1) WO2016165630A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112807318A (zh) * 2021-02-22 2021-05-18 广东盛普生命科技有限公司 1,2,3,4,6-o-五没食子酰葡萄糖在制备预防和/或治疗肺纤维化药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107325135A (zh) * 2017-09-05 2017-11-07 中国林业科学研究院林产化学工业研究所 一种1,2,3,4,6‑o‑五没食子酰葡萄糖标准样品的制备方法
EP3829664A4 (en) 2018-08-03 2022-05-04 Nectero Medical, Inc. PURIFIED PENTAGALLOYL GLUCOSE AND DELIVERY DEVICES
CN112444590B (zh) * 2019-09-02 2022-12-02 江阴天江药业有限公司 一种五倍子药材的uplc指纹图谱的构建方法、通过该方法构建的指纹图谱及其应用
CN113823364B (zh) * 2021-10-08 2023-08-01 武汉轻工大学 一种基于网络药理学分析1,2,3,4,6-o-五没食子酰葡萄糖治疗肝癌机制的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101525357A (zh) * 2008-03-07 2009-09-09 首都医科大学 一种从中药中分离制备五没食子酰基葡萄糖的方法
CN102526046A (zh) * 2010-12-14 2012-07-04 复旦大学 含有表没食子儿茶素没食子酸酯与索拉非尼的抗肿瘤药物组合物及其应用
CN103012510A (zh) * 2012-12-03 2013-04-03 北京工业大学 一种1,2,3,4,6-五没食子酰葡萄糖对照品的制备方法
CN103520229A (zh) * 2013-06-11 2014-01-22 浙江大学 一种芒果提取物在制备抗肿瘤药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730535A (zh) * 2007-02-15 2010-06-09 耶鲁大学 草药组合物phy906及其在化疗中的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101525357A (zh) * 2008-03-07 2009-09-09 首都医科大学 一种从中药中分离制备五没食子酰基葡萄糖的方法
CN102526046A (zh) * 2010-12-14 2012-07-04 复旦大学 含有表没食子儿茶素没食子酸酯与索拉非尼的抗肿瘤药物组合物及其应用
CN103012510A (zh) * 2012-12-03 2013-04-03 北京工业大学 一种1,2,3,4,6-五没食子酰葡萄糖对照品的制备方法
CN103520229A (zh) * 2013-06-11 2014-01-22 浙江大学 一种芒果提取物在制备抗肿瘤药物中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GILLIAN M. KEATING等: "Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma", 《DRUGS 2009》 *
YINHUI DONG等: "Involvement of autophagy induction in penta-1,2,3,4,6-O-galloyl-β-D-glucose-induced senescence-like growth arrest in human cancer cells", 《AUTOPHAGY》 *
李惠晨等: "五没食子酰基葡萄糖抗肿瘤的作用研究进展", 《现代肿瘤医学》 *
赵勇等: "中药水解类鞣质PGG的研究进展", 《临床和实验医学杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112807318A (zh) * 2021-02-22 2021-05-18 广东盛普生命科技有限公司 1,2,3,4,6-o-五没食子酰葡萄糖在制备预防和/或治疗肺纤维化药物中的应用
CN112807318B (zh) * 2021-02-22 2022-08-02 广东盛普生命科技有限公司 1,2,3,4,6-o-五没食子酰葡萄糖在制备预防和/或治疗肺纤维化药物中的应用

Also Published As

Publication number Publication date
US11000535B2 (en) 2021-05-11
WO2016165630A1 (zh) 2016-10-20
US20180214469A1 (en) 2018-08-02
JP6692830B2 (ja) 2020-05-13
JP2018517671A (ja) 2018-07-05
TWI626051B (zh) 2018-06-11
TW201637657A (zh) 2016-11-01

Similar Documents

Publication Publication Date Title
Liu et al. Garcinol: Current status of its anti-oxidative, anti-inflammatory and anti-cancer effects
Liu et al. Nuciferine, extracted from Nelumbo nucifera Gaertn, inhibits tumor-promoting effect of nicotine involving Wnt/β-catenin signaling in non-small cell lung cancer
CN107530368A (zh) 抗癌组合物及其用途
Bai et al. Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR 2 and miR-34a
Chen et al. Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α
Huang et al. Plumbagin triggers ER stress-mediated apoptosis in prostate cancer cells via induction of ROS
Liu et al. β-elemene regulates endoplasmic reticulum stress to induce the apoptosis of NSCLC cells through PERK/IRE1α/ATF6 pathway
Ma et al. Pachymic acid induces apoptosis via activating ROS-dependent JNK and ER stress pathways in lung cancer cells
Lu et al. Effects of cordycepin on HepG2 and EA. hy926 cells: Potential antiproliferative, antimetastatic and anti‑angiogenic effects on hepatocellular carcinoma
Wang et al. UVA irradiation enhances Brusatol‐mediated inhibition of melanoma growth by downregulation of the Nrf2‐mediated antioxidant response
Xiong et al. Ferruginol exhibits anticancer effects in OVCAR‑3 human ovary cancer cells by inducing apoptosis, inhibition of cancer cell migration and G2/M phase cell cycle arrest Retraction in/10.3892/mmr. 2021.11868
Park et al. Involvement of activation of the Nrf2/ARE pathway in protection against 6-OHDA-induced SH-SY5Y cell death by α-iso-cubebenol
Zhang et al. A purified biflavonoid extract from selaginella moellendorffii alleviates gout arthritis via NLRP3/ASC/Caspase-1 axis suppression
Yao et al. Punicalagin from pomegranate promotes human papillary thyroid carcinoma BCPAP cell death by triggering ATM-mediated DNA damage response
Zhao et al. Saikosaponin b2 enhances the hepatotargeting effect of anticancer drugs through inhibition of multidrug resistance-associated drug transporters
Li et al. Liriodenine induces the apoptosis of human laryngocarcinoma cells via the upregulation of p53 expression
Pan et al. Diosmetin inhibits cell growth and proliferation by regulating the cell cycle and lipid metabolism pathway in hepatocellular carcinoma
Amino et al. YM-201627: An orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation
Ke et al. Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma
Lin et al. Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway
Chen et al. Salvianolic acid B renders glioma cells more sensitive to radiation via Fis-1-mediated mitochondrial dysfunction
Yang et al. In vitro and in vivo anti-tumor activity of Coenzyme Q0 against TWIST1-overexpressing HNSCC cells: ROS-mediated inhibition of EMT/metastasis and autophagy/apoptosis induction
Chen et al. Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models
Li et al. Mogrol suppresses lung cancer cell growth by activating AMPK-dependent autophagic death and inducing p53-dependent cell cycle arrest and apoptosis
Huang et al. α-Cyperone protects dopaminergic neurons and inhibits neuroinflammation in LPS-induced Parkinson’s disease rat model via activating Nrf2/HO-1 and suppressing NF-κB signaling pathway

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180102